Nomad Power Solutions (NMAD) Share-based Compensation (2021 - 2026)
Nomad Power Solutions (NMAD) posted Share-based Compensation of $622231.0 for Q2 2026, down 53.69% on a QoQ basis from $1.3 million in Q4 2025, and up 132.18% year-over-year from $267999.0 in Q2 2025.
Analysis
Nomad Power Solutions (NMAD) Share-based Compensation (2021 - 2026) Analysis & Trends
Nomad Power Solutions has reported Share-based Compensation for 6 years, with the latest figure at $622231.0 in Q2 2026.
- On a quarterly basis, Share-based Compensation rose 132.18% year-over-year to $622231.0 in Q2 2026; TTM through Jun 2026 was $2.8 million, a 286.44% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 126.39% from the prior year.
- Share-based Compensation was $622231.0 for Q2 2026 at Nomad Power Solutions, down from $1.3 million in the prior quarter.
- The five-year high for Share-based Compensation was $1.3 million in Q4 2025, with the low at -$521734.0 in Q4 2022.
- Average Share-based Compensation over 5 years is $233019.9, with a median of $190052.5 recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation plunged 92.21% in 2024, then surged 1521.08% in 2025.
- Over 5 years, Share-based Compensation stood at -$521734.0 in 2022, then gained by 12.27% to -$457733.0 in 2023, then surged by 169.48% to $318020.0 in 2024, then surged by 322.49% to $1.3 million in 2025, then tumbled by 53.69% to $622231.0 in 2026.
- The last three Share-based Compensation figures came in at $622231.0 (Q2 2026), $1.3 million (Q4 2025), and $546499.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Nomad Power Solutions | 49.59 Mn | 49.59 Mn | - | 622,231.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 622,231.00 |
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 546,499.00 |
| Jun 30, 2025 | 267,999.00 |
| Mar 31, 2025 | 99,738.00 |
| Dec 31, 2024 | 318,020.00 |
| Sep 30, 2024 | 33,712.00 |
| Jun 30, 2024 | 33,345.00 |
| Mar 31, 2024 | 38,819.00 |
| Dec 31, 2023 | -457,733.00 |
| Sep 30, 2023 | 112,106.00 |
| Jun 30, 2023 | 428,229.00 |
| Mar 31, 2023 | 42,500.00 |
| Dec 31, 2022 | -521,734.00 |
| Sep 30, 2022 | 396,883.00 |
| Jun 30, 2022 | 424,094.00 |
| Jun 30, 2021 | 50,000.00 |